The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Primaquine Therapy for Malaria
Abstract
Primaquine is the only available drug for preventing relapse of malaria, and confusion surrounds its use. This review examines the wide range of clinical applications of primaquine described in the medical literature between 1946 and 2004. The risk of relapse of Plasmodium vivax malaria without primaquine therapy ranged from 5% to 80% or more, depending largely upon geographic location. Supervision of therapy profoundly impacts the risk of relapse, and almost all reports of malaria resistant to primaquine are associated with lack of such supervision. We nonetheless suspect that there is widespread resistance to the standard course of primaquine therapy, which is 15 mg primaquine base daily for 14 days. Clinical evidence confirms that a course of 15 mg daily for just 5 days, a regimen widely used in areas where malaria is endemic, has no discernible efficacy. This review supports a recommendation for a regimen of 0.5 mg/kg primaquine daily for 14 days, on the basis of superior efficacy and good tolerability and safety in nonpregnant persons without glucose-6-phosphate dehydrogenase deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bulletin of the World Health Organization
C., N. H. (1955) · The British Journal of Sociology · doi:10.2307/587237 · Cited by 3,601
The Journal of Laboratory and Clinical Medicine
(2003) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(03)00127-6 · Cited by 1,767
Indian Journal of Medical Research
(2024) · The Indian Journal of Medical Research · doi:10.25259/ijmr · Cited by 1,740
British Journal of Pharmacology
(2010) · British Journal of Pharmacology · doi:10.1111/(issn)1476-5381 · Cited by 920
Beutler, E. (1994) · Blood · doi:10.1182/blood.v84.11.3613.bloodjournal84113613 · Cited by 731
PLASMODIUM VIVAX RESISTANCE TO CHLOROQUINE?
Rieckmann, K. H., Davis, D. R., & Hutton, D. C. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91792-3 · Cited by 501
Coatney, G. R., Collins, W. E., Warren, M., & Contacos, P. G. (1971) · Cited by 454
Drug-Induced Methaemoglobinaemia Treatment Issues
Coleman, M. D., & Coleman, N. A. (1996) · Drug Safety · doi:10.2165/00002018-199614060-00005 · Cited by 275
Resistance to Chloroquine by Plasmodium vivax in Irian Jaya, Indonesia
Baird, J. K., Basri, H., Purnomo, Bangs, M. J., Subianto, B., Patchen, L. C., & Hoffman, S. L. (1991) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1991.44.547 · Cited by 232
Self-citationCompliance With Topical Timolol Treatment
Kass, M. A., Gordon, M., Morley, R. E., Meltzer, D. W., & Goldberg, J. J. (1987) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)74225-4 · Cited by 212
Cited by
Vivax Malaria: Neglected and Not Benign
Price, R. N., Tjitra, E., Guerra, C. A., Yeung, S., White, N. J., & Anstey, N. M. (2007) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2007.77.79 · Cited by 838
Comparative genomics of the neglected human malaria parasite Plasmodium vivax
Carlton, J. M., Adams, J. H., Silva, J. C., Bidwell, S. L., Lorenzi, H., Caler, E., Crabtree, J., Angiuoli, S. V., Merino, E. F., Amedeo, P., et al. (2008) · Nature · doi:10.1038/nature07327 · Cited by 835
Self-citationKey gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite
Mueller, I., Galinski, M. R., Baird, J. K., Carlton, J. M., Kochar, D. K., Alonso, P. L., & del Portillo, H. A. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70177-x · Cited by 661
Self-citationTjitra, E., Anstey, N. M., Sugiarto, P., Warikar, N., Kenangalem, E., Karyana, M., Lampah, D. A., & Price, R. N. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050128 · Cited by 611
Evidence and Implications of Mortality Associated with Acute Plasmodium vivax Malaria
Baird, J. K. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-12 · Cited by 398
Self-citationGlobal Epidemiology of Plasmodium vivax
Howes, R. E., Battle, K. E., Mendis, K. N., Smith, D. L., Cibulskis, R. E., Baird, J. K., & Hay, S. I. (2016) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.16-0141 · Cited by 418
Self-citationGlobal extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis
Price, R. N., von Seidlein, L., Valecha, N., Nosten, F., Baird, J. K., & White, N. J. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70855-2 · Cited by 388
Self-citationOperational strategies to achieve and maintain malaria elimination
Moonen, B., Cohen, J. M., Snow, R. W., Slutsker, L., Drakeley, C., Smith, D. L., Abeyasinghe, R. R., Rodriguez, M. H., Maharaj, R., Tanner, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61269-x · Cited by 381
Effectiveness of Antimalarial Drugs
Baird, J. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043207 · Cited by 375
Self-citationPrimaquine revisited six decades after its discovery
Vale, N., Moreira, R., & Gomes, P. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.08.011 · Cited by 367
WHO Guidelines for the treatment of malaria
Kunte, R., & Kunwar, R. (2011) · Medical Journal Armed Forces India · doi:10.1016/s0377-1237(16)30022-3 · Cited by 341
Chloroquine Resistance in Plasmodium vivax
Baird, J. K. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4075-4083.2004 · Cited by 335
Self-citationPRIMAQUINE: REPORT FROM CDC EXPERT MEETING ON MALARIA CHEMOPROPHYLAXIS I
HILL, D. R., BAIRD, J. K., PARISE, M. E., LEWIS, L. S., RYAN, E. T., & MAGILL, A. J. (2006) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2006.75.402 · Cited by 334
Self-citationPrimaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax Malaria
Bennett, J. W., Pybus, B. S., Yadava, A., Tosh, D., Sousa, J. C., McCarthy, W. F., Deye, G., Melendez, V., & Ockenhouse, C. F. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1301936 · Cited by 293
Geographical variation in Plasmodium vivax relapse
Battle, K. E., Karhunen, M. S., Bhatt, S., Gething, P. W., Howes, R. E., Golding, N., Van Boeckel, T. P., Messina, J. P., Shanks, G. D., Smith, D. L., et al. (2014) · Malaria Journal · doi:10.1186/1475-2875-13-144 · Cited by 282
Self-citationThe IMPROV Study Group (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1276-2 · Cited by 277
Robinson, L. J., Wampfler, R., Betuela, I., Karl, S., White, M. T., Li Wai Suen, C. S. N., Hofmann, N. E., Kinboro, B., Waltmann, A., Brewster, J., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001891 · Cited by 276
UK malaria treatment guidelines
Lalloo, D. G., Shingadia, D., Pasvol, G., Chiodini, P. L., Whitty, C. J., Beeching, N. J., Hill, D. R., Warrell, D. A., & Bannister, B. A. (2007) · Journal of Infection · doi:10.1016/j.jinf.2006.12.003 · Cited by 272
Neglect of Plasmodium vivax malaria
Baird, J. K. (2007) · Trends in Parasitology · doi:10.1016/j.pt.2007.08.011 · Cited by 266
Self-citationResistance to Therapies for Infection by Plasmodium vivax
Baird, J. K. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-09 · Cited by 262
Self-citationMalaria in pregnancy in the Asia-Pacific region
Rijken, M. J., McGready, R., Boel, M. E., Poespoprodjo, R., Singh, N., Syafruddin, D., Rogerson, S., & Nosten, F. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70315-2 · Cited by 181
Treating Severe Malaria in Pregnancy: A Review of the Evidence
Kovacs, S. D., Rijken, M. J., & Stergachis, A. (2015) · Drug Safety · doi:10.1007/s40264-014-0261-9 · Cited by 66
Metadata
- Authors
- Baird, J. K., & Hoffman, S. L.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-11-01
- Volume
- 39
- Issue
- 9
- Pages
- 1336-1345
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2158149195
- Cited by
- 435
- References
- 42
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.